Search
Friday 2 October 2015
  • :
  • :
Latest Update

Notable Stocks to Keep Your Eyes on: Lexington Realty Trust (NYSE:LXP), Oi SA (ADR) (NYSE:OIBR.C), Trinity Industries Inc (NYSE:TRN), Akorn, Inc. (NASDAQ:AKRX)

On Friday, Lexington Realty Trust (NYSE:LXP)’s shares declined -0.48% to $8.28.

Lexington Realty Trust (LXP) declared that it declared a regular common share/unit dividend/distribution for the quarter ending September 30, 2015 of $0.17 per common share/unit payable on or about October 15, 2015 to common shareholders/unitholders of record as of September 30, 2015.

Lexington also declared that it declared a cash dividend of $0.8125 per share of Series C Cumulative Convertible Preferred Stock (“Series C Preferred Shares”) for the quarter ending December 31, 2015. This Series C Preferred Share dividend is payable on or about February 16, 2016, to shareholders of record of Series C Preferred Shares as of January 29, 2016.

Lexington Corporate Properties Trust operates as a self-managed and self-administered real estate investment trust (REIT). The company acquires, owns, and manages a portfolio of office, industrial, and retail properties net-leased to corporate tenants in the United States.

Oi SA (ADR) (NYSE:OIBR)’s shares dropped -1.23% to $0.762.

Oi S.A. (OIBR) informs there is no discussion in progress about the restructuring of its debt and that it has not hired any banks to assist it in this subject.

NM Rothschild & Sons (Brasil) Ltda. has been hired to carry out an assessment work for the optimization of the use of the resources derived from the sale of PT Portugal SGPS S.A., with the purpose of extending the maturities and improving the Company’s debt profile.

Oi S.A. provides integrated telecommunication services for residential customers and governmental agencies, in addition to small, medium, and large companies in Brazil. It offers fixed-line voice services, such as installation, monthly subscription, metered services, collect calls, and supplemental local services; domestic and international long-distance services; broadband Internet access services; subscription television services; and bundled services, in addition to owns and operates public telephones. T

At the end of Friday’s trade, Trinity Industries Inc (NYSE:TRN)‘s shares surged 0.08% to $24.09.

Trinity Highway Products, LLC a wholly owned partner of Trinity Industries, Inc. (TRN), questions the circumstances under which the Virginia Department of Transportation (“VDOT”) is conducting a series of six crash tests on the Trinity Highway ET Plus® System.

Recently, the Texas A&M Transportation Institute (“TTI”), the designer of the ET Plus® System, released a statement that it has no confidence in the crash tests being performed by VDOT. Please see the following link for TTI’s statement: https://tti.tamu.edu/wp/wp-content/uploads/2014/12/TTI-Statement-on-Virginia-Crash-Tests-FINAL-09-18-15.pdf.

VDOT is conducting arbitrary, non-standard crash testing of the ET Plus® System. In Trinity Highway’s opinion, VDOT’s intention is to create the appearance that the product has failed crash tests for purposes of litigation. Trinity Highway shares TTI’s lack of confidence in the crash tests being performed by VDOT.

Trinity Industries, Inc. provides various products and services for the energy, transportation, chemical, and construction sectors in the United States and internationally. Its Rail Group segment offers railcars, counting autorack, box, covered hopper, gondola, intermodal, tank, and open hopper cars; and couplers, axles, and other equipment, in addition to railcar maintenance services.

Akorn, Inc. (NASDAQ:AKRX), ended its Friday’s trading session with -9.28% loss, and closed at $32.06.

Akorn, Inc. (AKRX), a leading specialty pharmaceutical company, declared that it has launched Doxercalciferol Injection Solution, 4 mcg/2 mL in 2mL single-use vials. The launch follows an approval of an abbreviated new drug application for the product from the U.S. Food and Drug Administration on May 7, 2015. Akorn’s product is therapeutically equivalent to Hectorol(R) injection, marketed by Genzyme Corporation.

Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products in the United States and internationally.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.




Leave a Reply

Your email address will not be published. Required fields are marked *